CLEAR Harmony was a Phase 3 clinical trial evaluating whether bempedoic acid (ETC-1002) is safe and well-tolerated over the long term in patients with high cardiovascular risk and LDL cholesterol not adequately controlled by existing therapies. Sponsored by Esperion Therapeutics, the trial compared bempedoic acid against placebo in people with hypercholesterolemia and established atherosclerotic cardiovascular disease. This trial was an important step in bringing a novel, non-statin LDL-lowering agent to market, particularly for patients who cannot tolerate statins or need additional cholesterol reduction beyond what statins alone can provide. The completed trial helped support FDA approval of bempedoic acid as an adjunct to diet and maximally tolerated statin therapy.
